CLOPIDOGREL VERSUS TICAGRELOR AND PRASUGREL IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH A NORMAL FUNCTION CYP2C19 GENE: A SUB-STUDY FROM THE POPULAR GENETICS

Daniel M.F. Claassens,Thomas O. Bergmeijer,Gerrit J.A. Vos,Rik Hermanides,Arnoud W.J. van t Hof,Pim van der Harst,Emanuele Barbato,Carmine Morisco,Richard M. Tjon Joe Gin,Folkert W. Asselbergs,Arend Mosterd,Jean-Paul R. Herrman,Willem J.M. Dewilde,Vera H.M. Deneer,Jurriën M. ten Berg

CLOPIDOGREL VERSUS TICAGRELOR AND PRASUGREL IN PRIMARY PERCUTANEOUS CORONARY INTERVENTION PATIENTS WITH A NORMAL FUNCTION CYP2C19 GENE: A SUB-STUDY FROM THE POPULAR GENETICS

2020

Daniel M.F. Claassens
Thomas O. Bergmeijer
Gerrit J.A. Vos
Rik Hermanides
Arnoud W.J. van t Hof
Pim van der Harst
Emanuele Barbato
Carmine Morisco
Richard M. Tjon Joe Gin
Folkert W. Asselbergs
Arend Mosterd
Jean-Paul R. Herrman
Willem J.M. Dewilde
Vera H.M. Deneer
Jurriën M. ten Berg

The POPular Genetics trial demonstrated that a genotype-guided strategy benefits patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) compared to standard treatment with ticagrelor or prasugrel by reducing bleedings, without increasing

Keywords:

Ticagrelor
Diabetes mellitus
Clopidogrel
CYP2C19
Percutaneous coronary intervention
Cardiology
Prasugrel
Medicine
Internal medicine
Conventional PCI
Myocardial infarction
Standard treatment
Genetics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations